Loading...
NPI 1619136413 · Dothan, AL · Hematology & Oncology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Jawaunna Blackmon is a hematology & oncology physician provider located in Dothan, Alabama. This profile covers 49 Medicare and 1 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Jawaunna Blackmon |
| Address | 287 Healthwest Dr |
| City | Dothan |
| State | AL |
| ZIP | 36303 |
| Taxonomy | Hematology & Oncology Physician |
| NPI Enumerated | June 6, 2008 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $2.1M |
| Medicaid | $0 |
This profile is consistent with an infusion‑centric hematology/oncology practice: the top revenue drivers are high-volume injectable oncology agents and chemotherapy administration codes, including J9271 (24.4K claims) and J0897 (21.7K claims), alongside chemotherapy administration codes such as 96413 and 96401 and supportive agents like J1627 and J0185. The presence of laboratory code 85025 and pump refill code 96521 further supports a clinic that delivers frequent on‑site infusions and associated monitoring services.
Revenue is heavily concentrated in a few drug codes: the precomputed top‑3 Medicare codes account for 76.6% of this provider’s total Medicare revenue, with J9271 reporting $1M (50.5% of total Medicare revenue), J0897 $391K (18.8%), and J1569 $153.2K (7.4%). This concentration implies that changes in reimbursement or utilization of these specific agents would materially affect the provider’s Medicare revenue.
The provider’s payer mix is effectively single‑payer on file: total Medicare revenue is $2.1M while reported Medicaid revenue is $0, indicating the practice relies on Medicare as its primary public payer and has no Medicaid billing recorded. This creates both operational dependence on Medicare reimbursement and potential vulnerability if payer mix shifts are required.
For denosumab (J0897) the provider ranks very highly nationally: rank #236 of 10057 providers and in the 98th percentile with the dataset label “notably above typical national volume.” That standing indicates the provider is a national high‑volume outlier for this bone‑modifying, infusion therapy and likely has significant capacity or clinical focus in indications that use denosumab.
Pembrolizumab (J9271) also drives the largest single share of Medicare revenue at $1M but is characterized in the data as typical/unremarkable volume despite being in the 87th percentile (rank #237 of 1841). Immune/oncology agents such as J9271 combined with J1569 (immune globulin) point to substantial immunotherapy use, though the rank/label suggests this provider’s pembrolizumab volume is not an extreme outlier versus national peers.
Multiple chemotherapy administration and supportive care codes sit in high national percentiles: 96413 ranks #274 of 7514 (96th percentile; notably above typical), 96367 ranks #85 of 4032 (98th percentile; notably above typical), and 96372 ranks #1513 of 58224 (97th percentile; notably above typical). These elevated percentiles across administration codes, together with tangible revenue contributions (96413 $62.5K; 96367 $19.3K; 96372 $5.2K), indicate above‑typical infusion throughput and operational emphasis on delivering parenteral cancer therapies.
Evaluation & management activity is also above typical for comparable providers: 99214 shows 953 claims and $85 paid/claim (4.1% of Medicare revenue) and ranks #12872 of 479517 (97th percentile; notably above typical), while 99215 ranks in the 94th percentile. This pattern of high E&M volume alongside infusion services is consistent with ongoing, longitudinal oncology care management for established patients.
The provider has an established NPI tenure (enumerated 2008-06-06, ~18 years ago), indicating a long‑standing presence in the market. Given the combination of long tenure, concentrated drug revenue (top 3 = 76.6%), and high infusion administration percentiles, strategic priorities for this practice would include managing payer contracting and utilization risk around its few revenue‑dominant drugs while leveraging its apparent infusion capacity in negotiations or care‑pathway arrangements.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
49 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | 24,400 | $40 | $1M |
| J0897 | Injection, denosumab, 1 mg | 21,720 | $20 | $391K |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | 4,380 | $40 | $153.2K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 950 | $90 | $85.8K |
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 690 | $90 | $62.5K |
| J1627 | Injection, granisetron, extended-release, 0.1 mg | 12,400 | $10 | $62K |
| Q5119 | Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 1,850 | $20 | $40.7K |
| J1437 | Injection, ferric derisomaltose, 10 mg | 2,200 | $20 | $37.4K |
| 99215 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the… | 250 | $130 | $32.8K |
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 2,720 | $10 | $21.8K |
Showing 1–10 of 49
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 49 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
49 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J9271 | 8 | 30 | 19,900 | $40 | $827.2K |
| J1569 | 7 | 10 | 5,120 | $40 | $179.3K |
| J0897 | 6 | 200 | 3,120 | $20 | $97.7K |
| J1627 | 3 | 10 | 14,400 | $1 | $69.9K |
| J1437 | 28 | 40 | 3,000 | $20 | $59.1K |
| Q5119 | 4 | 10 | 2,280 | $20 | $55.9K |
| 96413 | 7 | 150 | 150 | $90 | $20.2K |
| 99214 | 200 | 7,330 | 120 | $80 | $16.8K |
| 80053 | 544 | 670 | 140 | $10 | $13.1K |
| J0185 | 3 | 20 | 5,980 | $1 | $12.9K |
Showing 1–10 of 49
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
1 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 40 | $0 | $0 |
How this provider's Medicaid billing volume and revenue compare to other Alabama providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Alabama median
1 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 338 | 370 | 1,540 | $10 | $65K |
Other providers in the same ZIP code as Jawaunna Blackmon, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.